$GILD Recent Headlines Gilead's high pricing of Sovaldi

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2014 at 10:02 AM

$GILD Recent Headlines

Gilead's high pricing of Sovaldi draws inquiry from Senate committee 1:36 p.m. July 11, 2014 - blogs.marketwatch.com
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
S&P 500, Nasdaq retest major support 12:12 p.m. July 8, 2014 - Michael Ashbaugh
S&P 500, Nasdaq retest major support 11:57 a.m. July 8, 2014 - Michael Ashbaugh
Growth stocks are doing most bullish thing they can 3:23 p.m. July 1, 2014 - The Trading Deck
Robo-advisors, Syrian strikes and the stock-market shift they signal 6:45 a.m. June 25, 2014 - blogs.marketwatch.com
Health-care inflation heating back up 10:24 a.m. June 24, 2014 - blogs.marketwatch.com
Medtronic’s real problem is innovation, not taxation 6:45 a.m. June 19, 2014 - Tim Mullaney
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. June 18, 2014 - blogs.marketwatch.com
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com

Biogen's Profit Rolls Amid Recent Drug Launches 6:14 p.m. July 11, 2014 - Investors Business Daily
Senators Investigating Hepatitis C Drug Pricing 5:45 p.m. July 11, 2014 - The Wall Street Journal Interactive Edition
Senators Ask Gilead To Explain Sovaldi Pricing 10:35 a.m. July 11, 2014 - Investors Business Daily
Senators ask Gilead for Sovaldi pricing info 10:09 a.m. July 11, 2014 - Seeking Alpha
Trade-Ideas: Gilead (GILD) Is Today's New Lifetime High Stock 9:46 a.m. July 11, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:13 a.m. July 11, 2014 - benzinga.com
7 Most Heavily Shorted Nasdaq Stocks 8:43 a.m. July 11, 2014 - 247WallSt.com
J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views 3:31 p.m. July 10, 2014 - benzinga.com
My High Share Buyback And Dividend Growth Portfolio 2nd Quarter 2014 Update 12:05 p.m. July 10, 2014 - Seeking Alpha
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014 11:54 a.m. July 10, 2014 - TheStreet.com
Gilead Sciences Can Hit Par By The End Of The Year 11:35 a.m. July 10, 2014 - Seeking Alpha
A Pre-Earnings Update On Gilead 10:59 a.m. July 10, 2014 - Seeking Alpha
Gilead Sciences: Cause For Concern? 10:25 a.m. July 10, 2014 - Seeking Alpha
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) 6:27 a.m. July 10, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM 6:00 a.m. July 10, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains 7:53 p.m. July 9, 2014 - TheStreet.com
3 Drugs Stocks Driving The Industry Higher 1:03 p.m. July 9, 2014 - TheStreet.com
Grading Sobek's Mid-Year Biotech Stock Predictions 10:14 a.m. July 9, 2014 - TheStreet.com
Stock Market News for July 09, 2014 - Market News 10:06 a.m. July 9, 2014 - Zacks.com
Hottest Healthcare Stocks Now – SGEN GILD TEVA IRWD 8:30 a.m. July 9, 2014 - InvestorPlace.com

NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert 6:15 a.m. June 11, 2014 - Marketwire
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10 5:00 p.m. June 9, 2014 - BusinessWire - BZX
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. June 3, 2014 - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EQT Wraps Up Share Buyback with 4.3M Shares Repurchased

EQT's Bold Buyback: Crunching the Numbers Alright, let's peel back the curtain on EQT's latest maneuver—finishing up their share buyback program, all neat and tidy for 2026. They nailed down 707,203 of their own shares just in the first week of September, part of a grand total of 4,368,899 snatched up in the entire effort. That's a whopping SEK 1.448 billion invested in...

Baidu's Stock Connect Inclusion: What It Means for Investors

An Intriguing Move For Baidu's Class A Shares Well, here we go again, folks. Another move on the chessboard for Baidu. They've just walked their Class A ordinary shares onto the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects. As of today, September 7, 2026, mainland investors can now get their mitts on these shares more easily. It might not be a...

Kean-NJCU Merger: A Strategic Educational Move

The clock's ticked for Kean University and New Jersey City University, landing them into a fusion that's set tongues wagging across the education sector. This ain't just another day at the park—it’s a significant shift in the academic landscape that deserves a closer, sharper look. Behind the Curtains of Strategic Planning So, who’s behind the wheel charting this...

WEPSEA 2026 Propels Southeast Asia's Packaging Leap

Revolution in Packaging: Southeast Asia Steps Up Get ready for a wake-up call in the world of packaging, folks; the Southeast Asian market is taking a sharp turn toward sustainability and technological advancement, as highlighted by WEPSEA 2026's recent wrap-up in Shanghai. Far from a mere exhibition, this gathering served as the crucible for change, where old-school...

Cold Plasma Market Surges: $3.03 Billion by 2031

Cold Plasma's Rising Star in High-Tech Markets It's no secret that in the climb to technological dominance, industries are hunting for the next big play. Enter cold plasma. We're talking about a market anticipated to leap from USD 2.15 billion in 2026 to USD 3.03 billion by 2031. To those of us who've been grinding in the weeds of market trends, a 7.1% CAGR over half a...

vivo and UNESCO Unite Youth for Nature Stories

Young Creators Explore Nature Through a New Lens Pontremoli, Italy just became the backdrop for an extraordinary gathering of young visionaries. From August 31 to September 5, UNESCO’s Man and the Biosphere (MAB) Programme and vivo wrapped their 2026 Capture the Future initiative in the lush landscapes of the Appennino Tosco Emiliano Biosphere Reserve. It’s one thing...

Fosun Reaches New Heights in Hang Seng Sustainability

Fosun International's Sustainability Milestone Now, you don't often see a company's sustainability rating climbing the ladder like a homesick angel, but Fosun International just nailed it. On September 7, 2026, their Hang Seng Sustainability Rating bumped up a notch from AA- to AA+, now at an all-time high. It's the sort of financial footnote that grabs the attention....

Wooree Group Pushes for Rigorous Liposome Standards

Rallying for Rigorous Scientific Validation Ever find yourself pondering how many so-called 'innovative' health products really deliver what they promise? Let me tell ya, Wooree Group’s CEO, Ji-yong Yoon, ain’t buying into flimsy claims. At the Vitafoods Asia 2026 event in Bangkok, Yoon sent a clear message: Without scientific validation, calling a product 'liposomal'...

GBC 2026 Wraps Up: Korea Eyes Bio Industry Leadership

GBC 2026: Korea's Giant Leap in Bio Innovation Well, there wasn't a dull moment at the 'Global Bio Conference 2026' in Seoul. Picture a melting pot where 5,600 participants from 19 countries converged to chat about the latest and greatest in biopharma innovation and regulatory strategies. That's not a setup you see every day, mind you. This event packed the room with...

Yas Island's Bold Move: Expanding With Potter Magic

Potter Magic Takes Over Warner Bros. World Abu Dhabi Call it a stroke of wizardry or plain savvy business sense, Miral and Warner Bros. Discovery Global Experiences are betting large on Harry Potter with a trio of themed lands at Warner Bros. World Abu Dhabi. Brace yourselves, because this ain't your mother's theme park nostalgia—this is about breathing new life into a...